

## **Pathogenesis of Zika Virus Infection via Rectal Route**

Laura E. Martínez<sup>1</sup>, Gustavo Garcia Jr.<sup>1</sup>, Deisy Contreras<sup>1</sup>, Danyang Gong<sup>3</sup>, Ren Sun<sup>3</sup>,  
Vaithilingaraja Arumugaswami<sup>1,2,4\*</sup>

<sup>1</sup>Board of Governors Regenerative Medicine Institute, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA.

<sup>2</sup>Department of Surgery, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA.

<sup>3</sup>Department of Molecular and Medical Pharmacology, University of California at Los Angeles, Los Angeles CA 90095, USA.

<sup>4</sup>Department of Surgery, University of California at Los Angeles, Los Angeles CA 90095, USA.

Correspondence:

\*Vaithilingaraja Arumugaswami, MVSc., Ph.D.

Email: arumugaswami@cshs.org

## 1 Introduction

2  
3 **Zika virus (ZIKV) is a mosquito-borne flavivirus originally confined to Africa and Asia**  
4 **that has spread to islands located in Southeast Asia, and most recently to the Americas and**  
5 **the Caribbean. Approximately 80% of infected individuals are asymptomatic, while the**  
6 **remaining infected population exhibit mild febrile syndrome such as rash, conjunctivitis,**  
7 **and arthralgia. In some adults, ZIKV causes neurotropic Guillain–Barré syndrome<sup>1</sup>.**  
8 **Vertical transmission of ZIKV in infected mothers causes fetal growth restriction,**  
9 **microcephaly, and congenital eye disease<sup>2-5</sup>. Cases of ZIKV sexual transmission from male**  
10 **to female<sup>6-8</sup>, male to male<sup>9</sup>, and a suspected case of female to male transmission<sup>10</sup> have been**  
11 **reported. ZIKV has been detected in the semen of infected males<sup>11-15</sup>, even after months of**  
12 **symptom onset<sup>16-19</sup>. Viral persistence in the testes and semen can increase the risk of ZIKV**  
13 **transmission through rectal route in men having sex with men (MSM) and between**  
14 **heterosexual partners. The anorectal mucosa is a major entry site for HIV-1 transmission**  
15 **among MSM<sup>20</sup>, and for the acquisition and transmission of other sexually transmitted**  
16 **diseases, such as syphilis, chlamydia, and gonorrhea. Although the risk of ZIKV**  
17 **acquisition through the rectal route is high, no pathobiological information is available.**  
18 **Here, we describe the establishment of a rectal route of ZIKV infection system using**  
19 **immunocompromised (*ifnar1*<sup>-/-</sup>) male mice to determine their susceptibility to ZIKV and to**  
20 **assess viral dissemination to male reproductive organs. We found that rectal inoculation of**  
21 **ZIKV results in viremia with non-lethal infection. The rectal mucosa is susceptible to ZIKV**  
22 **entry and replication. Following rectal inoculation, ZIKV establishes active testicular**  
23 **infection that persists at least 21 days. During the acute phase of infection, the highest viral**  
24 **load was observed in the spleen, with inflammatory and immune cellular infiltration.**  
25 **Macrophages in the splenic red pulp are the target cells for ZIKV infection.**

26  
27 Mouse models of ZIKV pathogenesis have shown that mice deficient in type I IFN receptor  
28 (*ifnar1*<sup>-/-</sup> or A129) signaling pathway develop neurological disease in adults and congenital  
29 infection in pregnant females<sup>21-24</sup>. Adult immunocompetent (wild-type) mice are resistant to  
30 ZIKV infection due to a robust innate immune response that limits infection and spread. Thus,  
31 the *ifnar1*<sup>-/-</sup> mouse model has become a widely used *in vivo* system to investigate the  
32 pathogenesis of ZIKV diseases. Subcutaneous or intravaginal ZIKV infection of *ifnar1*<sup>-/-</sup> female

33 mice leads to the activation of systemic and localized immune responses and the establishment of  
34 congenital and neurological diseases<sup>23,25,26</sup>. Vaginal exposure of ZIKV during the first trimester  
35 of pregnancy leads to fetal growth restriction and brain infection in wild-type mice, and loss of  
36 pregnancy in *ifnar1*<sup>-/-</sup> mice<sup>26</sup>. In *ifnar1*<sup>-/-</sup> male mice, ZIKV robustly infects the brain, spinal cord,  
37 and testes<sup>22</sup>. ZIKV causes injury in the testes and epididymis of male mice, further reducing the  
38 levels of testosterone and oligospermia<sup>27</sup>. Moreover, ZIKV persists within the testes of *ifnar1*<sup>-/-</sup>  
39 mice following subcutaneous inoculation and causes testicular atrophy at 21 days post-  
40 infection<sup>28</sup>. ZIKV-mediated damage to the testes may lead to male infertility<sup>29</sup>. Recently, it was  
41 shown that intraperitoneally infected AG129 (interferon  $\alpha/\beta$  and  $-\gamma$  receptor knockout) male mice  
42 had persistent testicular infection for more than a month, and the semen contained infectious  
43 ZIKV from 1 to 3 weeks post-inoculation<sup>30</sup>. In addition, ZIKV infection was documented in 50%  
44 of female mice mated to infected non-vasectomized male mice<sup>30</sup>. Collectively, these findings  
45 provide important insights on the long-term potential effects of ZIKV infection of female and  
46 male reproductive organs. Currently, there is no knowledge regarding ZIKV acquisition via  
47 rectal route of infection. Further studies are needed to understand ZIKV replication and  
48 persistence within different tissue compartments after sexual transmission, including the rectal  
49 mucosa.

50  
51 In this study, we used *ifnar1*<sup>-/-</sup> mice to study the pathogenesis of ZIKV Asian genotype strain  
52 PRVABC59 in 4-6-week-old male mice by rectal inoculation ( $3.4 \times 10^6$  pfu per mouse), and  
53 followed disease progression for 21 days post-inoculation (dpi) (Fig. 1A). Mice were closely  
54 observed twice a day during the experimental period. Weight loss and neurological signs were  
55 monitored at various timepoints. We found that rectal inoculation of ZIKV does not cause  
56 mortality in *ifnar1*<sup>-/-</sup> male mice (Fig. 1B). Two of five infected mice showed lethargy and  
57 transient sickness, with relative body weight loss (12-14%) at 10 dpi (Fig. 1C). These mice were  
58 closely monitored and they steadily recovered by 21 dpi (Fig. 1C). In addition, infected mice  
59 showed peak viremia at 7 dpi (Fig. 1D). In an independent experiment, we tested the  
60 subcutaneous model of infection with PRVABC59 ( $2 \times 10^6$  pfu/mouse) to confirm its  
61 pathogenesis and development of lethal disease. Consistent with previous reports using A129  
62 mice<sup>31</sup>, subcutaneously infected mice demonstrated significant weight loss and eventually  
63 succumbed to infection (Supplementary Fig. 1A-C). Infected mice had high acute viremia as

64 early as 3 dpi and exhibited malaise, incoordination and neurological signs of posterior hind leg  
65 paralysis by 6 -7 dpi (Supplementary Fig. 1C-D).

66  
67 To assess ZIKV dissemination to the male reproductive system after rectal inoculation, we  
68 measured ZIKV genome copies in the testes and the accessory sex gland seminal vesicles, and  
69 the rectal mucosa at 3, 7 and 21 dpi by RT-qPCR. The rectal mucosa is lined by a single layer of  
70 columnar epithelial cells above the stroma that creates a mosaic of mucus-filled crypts. This  
71 simple columnar layer transitions into the stratified epithelium of the anal canal. We detected  
72 ZIKV replication within the rectal tissue at 3 dpi (Fig. 2A). ZIKV further disseminated to the  
73 testes and seminal vesicles, with peak acute viremic loads at 7 dpi (Fig. 2B), and persisted in the  
74 testes and rectal mucosa at 21 dpi (Fig. 2C). Future studies characterizing specific rectal cell  
75 types permissive to infection at earlier timepoints will provide insight on how ZIKV exploits this  
76 niche for replication and persistence.

77  
78 Rectal inoculation with ZIKV leads to viral dissemination to the brain at 3 dpi (Fig. 2A). Despite  
79 ZIKV infection of the brain, mice did not show malaise or neurological signs of disease at 7 dpi,  
80 as observed in subcutaneous route of infection. Some mice in the rectal route experiment showed  
81 little to no viral burden, while others sustained high viral loads in the brain ( $10^4$  - $10^6$  ZIKV  
82 genome copies/ $\mu$ g of RNA). However, subcutaneously infected mice showed comparable higher  
83 viral loads in the brain at 6 dpi ( $10^5$  copies) (Fig. 2D), further suggesting that the virus was  
84 causing a fundamentally different disease outcome in rectally-infected mice. Furthermore,  
85 rectally-infected mice showed significantly high viral loads in the spleen at 3 dpi that persisted to  
86 7 dpi (with a mean of  $6 \times 10^6$  copies) (Fig. 2A-B). In contrast, subcutaneously infected mice  
87 showed lower viral replication in the spleen (with  $\sim 10^4$  copies per mouse) at 6 dpi (Fig. 2D). It is  
88 likely that during rectal infection, the virus can enter through the rectal mucosa and gain access  
89 to the inferior mesenteric vein (IMV) to reach the spleen. Before joining the hepatic portal vein,  
90 the IMV connects to the splenic vein and mixing of infected blood from the rectum to splenic  
91 circulation can occur. Subcutaneous inoculation with ZIKV can result in rapid entry of infectious  
92 viral particles into the circulatory system to reach the target organ brain.

93

94 We then determined whether *ifnar1*<sup>-/-</sup> mice of reproductive age (12-week-old) would be able to  
95 control infection as efficiently as 4-6-week-old mice following rectal inoculation with ZIKV. 12-  
96 week-old mice did not succumb to infection nor showed signs of disease at 3 or 7 dpi  
97 (Supplementary Fig. 2). Infected mice were active and alert throughout the experimental period.  
98 Two of four infected mice showed relative body weight loss from day 5 to 7 and recovered by 10  
99 dpi, with clearing of the viremia at 14 dpi (Supplementary Fig. 2B-C). Similar to the  
100 experimental results of young mice, ZIKV disseminated to the testes, seminal vesicles, and brain,  
101 and caused robust infection of the spleen by 14 dpi (Supplementary Fig. 2D). The lack of  
102 observable differences between age groups suggests that rectal inoculation with ZIKV may  
103 provide protective immunity that limits lethal infection as compared to subcutaneous route of  
104 infection, which induces acute encephalitis and neurological disease in this model system.  
105

106 We then set out to investigate the cellular response to ZIKV infection in the spleens of 4-6-week-  
107 old mice in detail. Following rectal inoculation, ZIKV rapidly disseminated to the spleen at 3  
108 dpi, further causing splenomegaly by 7 dpi (Fig. 3A-B). To determine the immune cells  
109 contributing to the splenic response to infection, we performed immunohistochemistry using  
110 markers for CD11b<sup>+</sup> macrophages and dendritic cells, Ly6C<sup>+</sup> neutrophils or granulocytes, and  
111 CD4<sup>+</sup> T-cells. A rabbit polyclonal antibody recognizing ZIKV NS4B antigen was used to detect  
112 virus in the spleens of infected mice at 7 dpi. NS4B is a membrane bound cytoplasmic protein  
113 involved in flaviviral RNA genome replication. ZIKV infection caused infiltration or expansion  
114 of macrophages, dendritic cells, neutrophils, and CD4<sup>+</sup> T-cells to the spleen (Fig. 3C). To  
115 identify ZIKV target cell types in the spleen, we performed co-immunostaining of ZIKV NS4B  
116 with cell-specific markers anti-CD4, anti-Ly6C, anti-CD11b, or anti-F4/80 on consecutive tissue  
117 sections. Viral antigen was not detected in CD4<sup>+</sup> T-cells and neutrophils (Supplementary Fig. 3).  
118 Viral antigens were specifically found in the cytoplasm of F4/80<sup>+</sup> macrophages in the red pulp,  
119 outside of germinal centers (Fig. 3D and Supplementary Fig. 4). Further studies examining virus-  
120 specific immune responses in the rectal mucosa and within peripheral organs, including lymph  
121 nodes and spleen, may provide insight on how the immune system controls ZIKV infection  
122 following rectal route of exposure.  
123

124 During viral infection, there are active counter responses between the host and the virus, which  
125 often triggers the host's first-line of antiviral defense, an innate immune response<sup>32</sup>. This initial  
126 response is often measured by the induction of anti-viral and inflammatory cytokines at sites of  
127 active viral infection and tissue damage. Since the *ifnar1*<sup>-/-</sup> mice contain intact NF- $\kappa$ B, as well as  
128 type II and III IFN signaling pathways, we observed that ZIKV elicited a robust innate immune  
129 response in the rectum, testes, seminal vesicles, and brain at 7 dpi, as provided by the activation  
130 of key inflammation-related genes (Fig. 4). The pro-inflammatory marker, ICAM1, was highly  
131 expressed in the rectum, testes, seminal vesicles, and brain, but not in the spleen (Fig. 4A). ZIKV  
132 also elicited a strong IL-6 (Fig. 4B) and TNF $\alpha$  (Fig. 4C) response at these sites. The interferon  
133 stimulated gene OAS1 was highly expressed in all the tissues tested, including the spleen (Fig.  
134 4D), further suggesting a robust host response to infection mediated by an intrinsic cellular  
135 antiviral defense. During subcutaneous infection of ZIKV, systemic dissemination to the brain  
136 was not only confirmed by high viral load, but also by the vigorous IL-6 and ICAM1 response  
137 measured in the brains of infected mice (Fig. 4E). Overall, rectal inoculation of ZIKV prompts a  
138 robust initial innate immune response as observed by the expression of these pro-inflammatory  
139 and anti-viral cytokines, which can ultimately activate an anti-viral state to control infection. We  
140 expect that during rectal route of infection, ZIKV may stimulate stronger innate immune  
141 responses at the mucosal surface, which may further orchestrate the adaptive immune system to  
142 limit virus replication. This response can result in reduced tissue destruction and mortality.

143  
144 Our current understanding of rectal route of ZIKV infection and transmission is limited. In the  
145 current study, we determined that the rectal mucosa is permissive to ZIKV replication following  
146 rectal route of inoculation, which may provide significant implications for ZIKV transmission  
147 via anorectal route among MSM and heterosexual partners. Our experiments with  
148 immunocompromised male mice show that ZIKV disseminates to the testes and seminal vesicles  
149 following rectal inoculation. The testes are considered an "immunoprivileged replication site" for  
150 ZIKV. Our study shows that ZIKV actively replicates in the testes at least 21 days post-  
151 infection, suggesting that the testes may provide a reservoir for active viral presence to  
152 perpetuate transmission. Semen, pre-ejaculate, or blood (via rectal damage or lacerations) may  
153 also contribute to ZIKV transmission via anorectal route. Therefore, studies examining the use of  
154 viricide to limit ZIKV entry to the rectal mucosa are critical. Moreover, rectal route of

155 immunization against Rotavirus virus-like particles<sup>33</sup> or a Hepatitis A virus vaccine<sup>34</sup>, have been  
156 shown to elicit strong systemic humoral responses. Our model system of rectal infection can be  
157 used as a platform to study immunization against ZIKV and to further understand the long-term  
158 effect of infection on mucosal immunity. It provides the opportunity for further exploring the  
159 impact of ZIKV persistence on male reproductive health and maternal transmission.

160

## 161 **Methods**

162

163 **Ethics Statement.** This study was performed in strict accordance with the recommendations of  
164 the Guide for the Care and Use of Laboratory Animal. The institutional Animal Care Use  
165 Committee of the Cedars-Sinai Medical Center approved the study.

166

167 **Cell lines and virus.** *Aedes albopictus* mosquito C6/36 cell line (CRL-1660 cell line from  
168 ATCC) was used for propagating virus. C6/36 cells were maintained at 30°C in Dulbecco's  
169 Modified Eagle's Medium (Sigma Aldrich) supplemented with 10% heat-inactivated fetal bovine  
170 serum (FBS) (Gemini) with 100 U/mL penicillin (GIBCO) and 100 µg/mL streptomycin  
171 (GIBCO). Vero cells were obtained from ATCC and were cultured in DMEM supplemented with  
172 10% FBS, penicillin and streptomycin, 1X GlutaMax (GIBCO), and 20 mM HEPES (GIBCO).  
173 The ZIKV PRVABC59 strain was received from the Center for Disease Control (CDC).  
174 Working ZIKV stocks were prepared by infecting C6/36 cells. Supernatants were collected and  
175 centrifuged at 200 g at 4°C for 10 min to remove cellular debris, aliquoted, and frozen at -80°C.

176

177 **Quantification of ZIKV by plaque assay.** Monolayers of Vero cells were plated on 12-well  
178 plates. Virus supernatants from C6/36 cells were tittered by making dilutions in DMEM and  
179 were added to Vero cell monolayers at 37°C for 4 hours. Then, complete medium was added.  
180 Two days following the infection, plaques were counted manually as previously described<sup>35</sup>.

181

182 **Rectal inoculation of A129 mice.** Pathogen-free *ifnar1* receptor-deficient mice (B6.129S2-  
183 *Ifnar1<sup>tm1Agt</sup>/Mmjax* or A129) were purchased from the Mutant Mouse Resource and Research  
184 Centers (MMRRC) supported by NIH. 4-6-week-old *ifnar1<sup>-/-</sup>* male mice were rectally inoculated  
185 with PBS or ZIKV (PRVABC59, Puerto Rico 2015) while anesthetized. N=5-6 mice per group.

186 Briefly, a calginate swab was used to remove fecal stain from the anal orifice. For rectal ZIKV  
187 inoculation, each mouse was inoculated with  $3.4 \times 10^6$  plaque forming units (pfu) in a volume of  
188 20  $\mu$ l using a sterile smooth pipette tip (after passing or penetrating through anal orifice). Mice  
189 were kept with the rectum facing upwards for 4 minutes to reduce leakage of the inoculum.  
190 Survival, weight loss, and symptoms were monitored for 3, 7 and 21 days post-rectal inoculation  
191 (dpi). For the older mice study (12-week-old), rectal inoculated mice were infected for 14 days  
192 as described above. At the indicated post-infection times, mice were humanly euthanized using  
193 CO<sub>2</sub> and blood was collected for viremia. To measure ZIKV viremia, 25  $\mu$ l of blood was  
194 collected by direct cardiac puncture at the indicated timepoints post-infection. Total blood RNA  
195 was extracted using the viral RNA mini kit (Qiagen). The rectum, testes, seminal vesicles,  
196 spleen, and brain were harvested for evaluating viral load and cellular gene expression, as well as  
197 for immunohistochemistry. Tissues were removed from ZIKV infected mice or uninfected (PBS)  
198 control mice and dissected in thirds for fixation in 10% neutral buffered formalin, 4%  
199 paraformaldehyde, or RNAlater (Thermo Fisher Scientific) for RNA isolation.

200

201 **Subcutaneous inoculation of A129 mice.** For subcutaneous (SC) infections with ZIKV, 4-6-  
202 week-old *ifnar1*<sup>-/-</sup> male mice were inoculated with PBS (n=4 mice) or ZIKV (2 x 10<sup>6</sup> pfu per  
203 mouse in a 40  $\mu$ l volume) (n=4 mice) in the hind limb region. Blood was collected for viremia at  
204 3 and 6 dpi, and the brain and spleen were harvested for viral load.

205

206 **RNA sample preparation and RT-qPCR.** To determine levels of virus in tissues of control and  
207 infected mice, tissues were placed in RNAlater (Thermo Fisher Scientific) immediately after  
208 harvest and stored at -80°C. Tissues were homogenized and RNA was extracted using TRIzol as  
209 per the manufacturer (Thermo Fisher Scientific). Total RNA was isolated from rectum, testes,  
210 seminal vesicles, spleen, and brain. RNA was quantified using a NanoDrop 1000  
211 Spectrophotometer (Thermo Fisher Scientific). cDNA was prepared from 1  $\mu$ g of RNA using  
212 random hexamer primers and the SuperScript III Reverse Transcriptase Kit (Thermo Fischer  
213 Scientific). QPCR was performed using SYBR Green ROX Supermix (Life Technologies) and a  
214 QuantStudio 12K Flex Real-Time PCR System (ABI Thermo Fisher Scientific). Briefly, the  
215 amplification was performed using 10  $\mu$ l volume reactions in a 384-well plate format with the  
216 following conditions: 50°C for 2 minutes followed by 95°C for 2 minutes, then 40 cycles at 95°C

217 for 15 seconds and 60°C for 1 minute. The relative concentration of each transcript was  
218 calculated using the  $2^{-\Delta CT}$  method and Glyceraldehyde 3-phosphate dehydrogenase (GAPDH)  
219 threshold cycle ( $C_T$ ) values were used for normalization. The basal mRNA level in tissue from  
220 the PBS-inoculated group was normalized to 1 and the fold change relative to basal was  
221 determined for each tissue type. The qPCR primer pairs for the mRNA transcript targets are  
222 provided in Supplementary Table 1. ZIKV RNA transcript levels were quantified by comparing  
223 to a standard curve generated using dilutions ( $10^1$ - $10^9$  copies) of a ZIKV NS5 gene containing  
224 plasmid. ZIKV RNA levels are expressed as ZIKV genome copies per 1  $\mu$ g of RNA using the  
225 standard curve.

226

227 **Immunohistochemistry.** Tissue was incubated in 4% PFA for an hour and transferred to PBS.  
228 Tissues were then submerged in 10%, 20%, and 30% sucrose for an hour each. Tissue was then  
229 embedded in OCT (Fisher Healthcare) and incubated overnight at -80°C. Tissues were cut (10  
230  $\mu$ m thick) using a Leica cryostat microtome and mounted on Super Frost microscope slides  
231 (VWR). Sections were washed 3 times and permeabilized using blocking buffer (0.3% Triton X-  
232 100, 0.1% BSA, in 1 X PBS) for 1 hour at room temperature. For ZIKV staining, sections were  
233 incubated overnight at 4°C with a polyclonal anti-Zika NS4B antibody (rabbit, 1:250)  
234 (GeneTex). The sections were then rinsed with 1X PBS three times and incubated with  
235 secondary antibody, Alexa Fluor-conjugated 488 antibody (raised in rabbit; 1:1000), for 1 hour  
236 at room temperature. The antibodies used for immune cell staining are listed in Supplementary  
237 Table 2. For immune cell staining, Anti-Ly6C was used to immunostain monocytes, neutrophils,  
238 or granulocytes; anti-CD11b for monocytes, macrophages, and dendritic cells; anti-CD4 for  
239 CD4<sup>+</sup> T-cells, and anti-F4/80 for macrophages. The secondary antibody, Alexa Fluor-conjugated  
240 555 (1:1000), was used for visualization of immune cell infiltrates. Nucleus was stained with  
241 DAPI (4',6-Diamidino-2-Phenylindole, Dihydrochloride) (Life Technologies) at a dilution of  
242 1:1000 in blocking buffer.

243

244 **Data analysis.** All testing was done at the two-sided alpha level of 0.05. Data were analyzed for  
245 statistical significance using the parametric two-tailed unpaired *t*-test Mann Whitney to compare  
246 two groups (uninfected vs. infected) with Graph Pad Prism software, version 7.0 (GraphPad

247 Software, US). Kaplan-Meier survival curves were analyzed by the Gehan-Breslow-Wilcoxon  
248 test. *p*-values less than 0.05 were considered significant.

249

250 **Acknowledgments.** We thank Leslie Garcia for assistance with tissue cryosectioning and  
251 preparation, and Preeti Hadavale and Constance Yue for help with immunohistochemistry. This  
252 research was funded by Cedars-Sinai Medical Center's Institutional Research Award to V.A. and  
253 UCLA institutional support to R.S.

254

255 **Author contributions.** L.E.M and V.A. designed the study. L.E.M, G.G, D.C, and V.A.  
256 performed experiments. L.E.M. and D.C. performed data analysis and interpretation. L.E.M,  
257 G.G., D.C., and V.A. wrote the manuscript.

258

#### 259 **Additional information**

260 Supplementary information is available for this paper. Correspondence and requests for materials  
261 should be addressed to V.A.

262

#### 263 **Competing interests**

264 The authors declare no competing financial interests.

265

266

267

268

269

270

271

272

273

274

275

276

277

## 278 **References**


279

- 280 1 Cao-Lormeau, V. M. *et al.* Zika virus, French polynesia, South pacific, 2013. *Emerg Infect*  
281 *Dis* **20**, 1085-1086, doi:10.3201/eid2006.140138 (2014).
- 282 2 Ventura, C. V., Maia, M., Bravo-Filho, V., Gois, A. L. & Belfort, R., Jr. Zika virus in  
283 Brazil and macular atrophy in a child with microcephaly. *Lancet* **387**, 228,  
284 doi:10.1016/S0140-6736(16)00006-4 (2016).
- 285 3 Ventura, C. V., Maia, M., Dias, N., Ventura, L. O. & Belfort, R., Jr. Zika: neurological and  
286 ocular findings in infant without microcephaly. *Lancet* **387**, 2502, doi:10.1016/S0140-  
287 6736(16)30776-0 (2016).
- 288 4 Ventura, C. V. *et al.* Risk Factors Associated With the Ophthalmoscopic Findings  
289 Identified in Infants With Presumed Zika Virus Congenital Infection. *JAMA Ophthalmol*  
290 **134**, 912-918, doi:10.1001/jamaophthalmol.2016.1784 (2016).
- 291 5 Ventura, C. V. *et al.* Optical Coherence Tomography of Retinal Lesions in Infants With  
292 Congenital Zika Syndrome. *JAMA Ophthalmol* **134**, 1420-1427,  
293 doi:10.1001/jamaophthalmol.2016.4283 (2016).
- 294 6 Hills, S. L. *et al.* Transmission of Zika Virus Through Sexual Contact with Travelers to  
295 Areas of Ongoing Transmission - Continental United States, 2016. *MMWR Morb Mortal*  
296 *Wkly Rep* **65**, 215-216, doi:10.15585/mmwr.mm6508e2 (2016).
- 297 7 Moreira, J., Peixoto, T. M., Machado de Siqueira, A. & Lamas, C. C. Sexually acquired  
298 Zika virus: a systematic review. *Clin Microbiol Infect*, doi:10.1016/j.cmi.2016.12.027  
299 (2017).
- 300 8 Russell, K. *et al.* Male-to-Female Sexual Transmission of Zika Virus-United States,  
301 January-April 2016. *Clin Infect Dis* **64**, 211-213, doi:10.1093/cid/ciw692 (2017).
- 302 9 Deckard, D. T. *et al.* Male-to-Male Sexual Transmission of Zika Virus--Texas, January  
303 2016. *MMWR Morb Mortal Wkly Rep* **65**, 372-374, doi:10.15585/mmwr.mm6514a3  
304 (2016).
- 305 10 Davidson, A., Slavinski, S., Komoto, K., Rakeman, J. & Weiss, D. Suspected Female-to-  
306 Male Sexual Transmission of Zika Virus - New York City, 2016. *MMWR Morb Mortal*  
307 *Wkly Rep* **65**, 716-717, doi:10.15585/mmwr.mm6528e2 (2016).
- 308 11 Atkinson, B. *et al.* Detection of Zika Virus in Semen. *Emerg Infect Dis* **22**, 940,  
309 doi:10.3201/eid2205.160107 (2016).
- 310 12 Gaskell, K. M., Houlihan, C., Nastouli, E. & Checkley, A. M. Persistent Zika Virus  
311 Detection in Semen in a Traveler Returning to the United Kingdom from Brazil, 2016.  
312 *Emerg Infect Dis* **23**, 137-139, doi:10.3201/eid2301.161300 (2017).
- 313 13 Harrower, J. *et al.* Sexual Transmission of Zika Virus and Persistence in Semen, New  
314 Zealand, 2016. *Emerg Infect Dis* **22**, 1855-1857, doi:10.3201/eid2210.160951 (2016).
- 315 14 Mansuy, J. M. *et al.* Zika virus: high infectious viral load in semen, a new sexually  
316 transmitted pathogen? *Lancet Infect Dis* **16**, 405, doi:10.1016/S1473-3099(16)00138-9  
317 (2016).
- 318 15 Mansuy, J. M. *et al.* Zika virus in semen of a patient returning from a non-epidemic area.  
319 *Lancet Infect Dis* **16**, 894-895, doi:10.1016/S1473-3099(16)30153-0 (2016).
- 320 16 Matheron, S. *et al.* Long-Lasting Persistence of Zika Virus in Semen. *Clin Infect Dis* **63**,  
321 1264, doi:10.1093/cid/ciw509 (2016).

- 322 17 Atkinson, B. *et al.* Presence and Persistence of Zika Virus RNA in Semen, United  
323 Kingdom, 2016. *Emerg Infect Dis* **23**, doi:10.3201/eid2304.161692 (2017).
- 324 18 Nicastrì, E. *et al.* Persistent detection of Zika virus RNA in semen for six months after  
325 symptom onset in a traveller returning from Haiti to Italy, February 2016. *Euro Surveill*  
326 **21**, doi:10.2807/1560-7917.ES.2016.21.32.30314 (2016).
- 327 19 Oliveira Souto, I. *et al.* Persistence of Zika virus in semen 93 days after the onset of  
328 symptoms. *Enferm Infecc Microbiol Clin*, doi:10.1016/j.eimc.2016.10.009 (2016).
- 329 20 Catania, J. A. *et al.* The continuing HIV epidemic among men who have sex with men. *Am*  
330 *J Public Health* **91**, 907-914 (2001).
- 331 21 Aliota, M. T. *et al.* Characterization of Lethal Zika Virus Infection in AG129 Mice. *PLoS*  
332 *Negl Trop Dis* **10**, e0004682, doi:10.1371/journal.pntd.0004682 (2016).
- 333 22 Lazear, H. M. *et al.* A Mouse Model of Zika Virus Pathogenesis. *Cell Host Microbe* **19**,  
334 720-730, doi:10.1016/j.chom.2016.03.010 (2016).
- 335 23 Miner, J. J. *et al.* Zika Virus Infection during Pregnancy in Mice Causes Placental Damage  
336 and Fetal Demise. *Cell* **165**, 1081-1091, doi:10.1016/j.cell.2016.05.008 (2016).
- 337 24 Rossi, S. L. *et al.* Characterization of a Novel Murine Model to Study Zika Virus. *Am J*  
338 *Trop Med Hyg* **94**, 1362-1369, doi:10.4269/ajtmh.16-0111 (2016).
- 339 25 Khan, S. *et al.* Dampened antiviral immunity to intravaginal exposure to RNA viral  
340 pathogens allows enhanced viral replication. *J Exp Med* **213**, 2913-2929,  
341 doi:10.1084/jem.20161289 (2016).
- 342 26 Yockey, L. J. *et al.* Vaginal Exposure to Zika Virus during Pregnancy Leads to Fetal Brain  
343 Infection. *Cell* **166**, 1247-1256 e1244, doi:10.1016/j.cell.2016.08.004 (2016).
- 344 27 Govero, J. *et al.* Zika virus infection damages the testes in mice. *Nature* **540**, 438-442,  
345 doi:10.1038/nature20556 (2016).
- 346 28 Uraki, R. *et al.* Zika virus causes testicular atrophy. *Sci Adv* **3**, e1602899,  
347 doi:10.1126/sciadv.1602899 (2017).
- 348 29 Ma, W. *et al.* Zika Virus Causes Testis Damage and Leads to Male Infertility in Mice. *Cell*  
349 **168**, 542, doi:10.1016/j.cell.2017.01.009 (2017).
- 350 30 Duggal, N. K. *et al.* Frequent Zika Virus Sexual Transmission and Prolonged Viral RNA  
351 Shedding in an Immunodeficient Mouse Model. *Cell Rep* **18**, 1751-1760,  
352 doi:10.1016/j.celrep.2017.01.056 (2017).
- 353 31 Manangeeswaran, M., Ireland, D. D. & Verthelyi, D. Zika (PRVABC59) Infection Is  
354 Associated with T cell Infiltration and Neurodegeneration in CNS of Immunocompetent  
355 Neonatal C57Bl/6 Mice. *PLoS Pathog* **12**, e1006004, doi:10.1371/journal.ppat.1006004  
356 (2016).
- 357 32 Katze, M. G., Fornek, J. L., Palermo, R. E., Walters, K. A. & Korth, M. J. Innate immune  
358 modulation by RNA viruses: emerging insights from functional genomics. *Nat Rev*  
359 *Immunol* **8**, 644-654, doi:10.1038/nri2377 (2008).
- 360 33 Parez, N. *et al.* Rectal immunization with rotavirus virus-like particles induces systemic  
361 and mucosal humoral immune responses and protects mice against rotavirus infection. *J*  
362 *Virol* **80**, 1752-1761, doi:10.1128/JVI.80.4.1752-1761.2006 (2006).
- 363 34 Mitchell, L. A. & Galun, E. Rectal immunization of mice with hepatitis A vaccine induces  
364 stronger systemic and local immune responses than parenteral immunization. *Vaccine* **21**,  
365 1527-1538 (2003).
- 366 35 Contreras, D. & Arumugaswami, V. Zika Virus Infectious Cell Culture System and the In  
367 Vitro Prophylactic Effect of Interferons. *J Vis Exp*, doi:10.3791/54767 (2016).

368 **Figures**

369




370

371 **Figure 1. Rectal inoculation of ZIKV in *ifnar1*<sup>-/-</sup> male mice results in a non-lethal, self-**  
372 **limiting infection with viremia.** (A) Schematic showing the infection timeline for PBS  
373 (uninfected) and ZIKV infected groups. (B) Kaplan-Meier survival plot shows percent survival  
374 of *ifnar1*<sup>-/-</sup> male mice post-rectal inoculation with PBS (n=5) or ZIKV (n=6). (C) Body weight  
375 change, represented as a percentage, of male mice post-rectal inoculation. Error bars represent  
376 the standard deviation (SD). (D) Viremia in uninfected and infected mice at 3, 7, and 21 dpi.  
377 Individual mice are represented by circles (PBS) or diamonds (ZIKV), with means represented  
378 by black lines. Two-tailed unpaired, non-parametric Mann-Whitney tests were conducted, where  
379 \*p < 0.05 and \*\*p < 0.001. ns, non-significant.

380

381




382

383 **Figure 2. Tissue viral load following rectal and subcutaneous routes of ZIKV inoculation.**  
384 Graphs depict ZIKV genome copies detected by RT-qPCR in various tissues at 3 dpi (A), 7 dpi  
385 (B), and 21 dpi (C). Each symbol corresponds to data from an individual mouse. n=5-6 mice per  
386 group. (D) Viral load in the spleen and brain at 6 days post-subcutaneous infection with ZIKV.  
387 n=4 mice per group. Two-tailed unpaired, non-parametric Mann-Whitney tests were conducted,  
388 where \*p < 0.05 and \*\*p < 0.001.

389


390

391



392

393 **Figure 3. ZIKV induces splenomegaly and infiltration of inflammatory cells in spleen after**  
394 **rectal route of infection.** (A) Graph shows spleen weight at 7 and 21 days post-rectal  
395 inoculation. (B) Gross image of spleens from PBS and ZIKV infected mice at 7 dpi. (C)  
396 Inflammatory and immune cellular infiltrates in the spleen of PBS and ZIKV inoculated mice at  
397 7 dpi. Panels depict spleen tissue immunostained with anti-Ly6C, anti-CD11b, and anti-CD4. (D)  
398 Spleen tissue immunostained for ZIKV antigen NS4B. Anti-F4/80 was used to detect  
399 macrophages in the spleen. Merged images show viral antigen within the cytoplasm of F4/80<sup>+</sup>  
400 macrophages in the red pulp of the spleen. Nuclei was stained with DAPI. Scale bar, 25  $\mu$ m. The  
401 images (20X) are representative of 5-6 different animals for PBS and ZIKV groups.



402

403 **Figure 4. Tissue expression of inflammation-related genes at 7 days post-rectal inoculation**  
404 **with ZIKV.** Expression of inflammation-related genes in the rectum, testes, seminal vesicles,  
405 brain, and spleen at 7 dpi. Total RNA was extracted from tissue and relative mRNA levels of  
406 ICAM1 (A), IL-6 (B), TNF- $\alpha$  (C), and OAS1 (D) were determined by RT-qPCR and normalized  
407 to GAPDH. The basal mRNA level in tissue from the PBS-inoculated group was normalized to 1  
408 for each tissue type and the fold change relative to basal is shown. (E) Levels of ICAM1 and IL-  
409 6 in the brain of mice subcutaneously infected with ZIKV at 6 dpi.

410

411

412

413


414

415

416

417

### Supplementary Information



418


419 **Supplementary Figure 1.**

420

421

422

423



424

425 **Supplementary Figure 2.**

426

427

428


429

430


431

432

433



456 Supplementary Figure 3.



457

458 **Supplementary Figure 4.**

459

460

461

462

463

464

465

466

467

468

469

470 **Supplementary Table 1. RT-qPCR primer sequences**

<b>Primer</b>	<b>Forward primer</b>	<b>Reverse primer</b>
ZIKV	AAGTACACATACCAAAACAAAGTGGT	TCCGCTCCCCCTTTGGTCTTG
ICAM1	GTTCTCTAATGTCTCCGAGGC	CTTCAGAGGCAGGAAACAGG
IL-6	CAAAGCCAGAGTCCTTCAGAG	GTCCTTAGCCACTCCTTCTG
TNF $\alpha$	CTTCTGTCTACTGAACTTCGGG	CAGGCTTGTCACTCGAATTTTG
OAS1	AGAGATGCTTCCAAGGTGC	ACTGATCCTCAAAGCTGGTG

471

472

473

474

475

476

477

478

479

480

481

482

483

484

485 **Supplementary Table 2. Reagents or resources used in this study**

<b>Reagent</b>	<b>Source</b>	<b>Identifier</b>
<b>Cell lines</b>		
<i>Aedes albopictus</i> mosquito, clone C6/36	ATCC	CRL-1660
Vero, African green monkey	ATCC	CCL-81
<b>Virus</b>		
PRVABC59	CDC	Drs. Aaron Brault and Brandy Russell
<b>Antibodies</b>		
Anti-mouse F4/80, BM8	eBioscience	Catalog No: 14-4801-81
Anti-mouse CD4, clone OX-38	BD Biosciences	Catalog No: 550297
Anti-mouse Ly6C, clone HK1.4	Biolegend	Catalog No: 128012
Zika virus NS4B protein antibody, rabbit polyclonal	GeneTex	Catalog No: GTX133311
Goat anti-rabbit Alexa Flour-488	ThermoFisher Scientific	Catalog No: A-11008
Goat anti-mouse Alexa Flour-555	ThermoFisher Scientific	Catalog No: A32727
<b>Reagents</b>		
QIAamp Viral RNA Mini Kit	Qiagen	Catalog No: 52904
Platinum SYBR Green qPCR SuperMix-UDG w/ Rox	ThermoFisher Scientific	Catalog No: 11744500

486

487

488

489

490

491

492

493

494

495

496

497

498 **Supplementary Figure 1. Subcutaneous infection with ZIKV causes weight loss, posterior**  
499 **hind limb paralysis, and mortality in *ifnar1*<sup>-/-</sup> mice. Related to Figure 1.** (A) Kaplan-Meier  
500 survival plot and (B) body weight change of PBS and ZIKV-infected mice via subcutaneous  
501 route. (C) A mouse (right) in the infected group shows hind limb posterior paralysis at 6 dpi. (D)  
502 Viremia at 3 and 6 dpi. Two-tailed unpaired, non-parametric Mann-Whitney tests were  
503 conducted, where \* $p < 0.05$  and \*\* $p < 0.001$ .

504 **Supplementary Figure 2. ZIKV burden at 14 days post-rectal inoculation of 12-week-old**  
505 **male mice. Related to Figures 1 and 2.** (A) Kaplan-Meier survival plot of PBS (n=3) and ZIKV  
506 (n=4) infected groups. (B) Graph presents percent body weight change at various timepoints  
507 post-rectal inoculation. (C) Viremia in PBS and ZIKV-infected mice at 14 dpi. (D) Tissue viral  
508 load at 14 dpi. Each symbol corresponds to data from an individual mouse. Two-tailed unpaired,  
509 student t-tests were conducted, where \* $p < 0.05$  and \*\* $p < 0.001$ \*\*.

510 **Supplementary Figure 3. ZIKV antigens were not present in immune cells of the spleen.**  
511 *Related to Figure 3C.* Uninfected and ZIKV infected spleen tissue at 7 dpi were co-  
512 immunostained with ZIKV NS4B and anti-CD4 (A), anti-Ly6C (B), or anti-CD11b (C). Nuclei  
513 was stained with DAPI. Scale bar, 25  $\mu\text{m}$ . The images (20X) are representative of 5 different  
514 mice for PBS and 6 mice for the ZIKV infected group.

515 **Supplementary Figure 4. ZIKV antigens localize with splenic macrophages within the red**  
516 **pulp of the spleen after rectal route of infection. Related to Figure 3D.** Uninfected and ZIKV  
517 infected spleen at 7 dpi were immunostained for ZIKV protein NS4B and macrophages using  
518 anti-F4/80 antibody. Merged images show ZIKV antigens present in the cytoplasm of F4/80<sup>+</sup>  
519 macrophages within the red pulp (RP) of the spleen. White pulp, WP. Nuclei was stained with  
520 DAPI. Scale bar, 100  $\mu\text{m}$ . The images (4X) are representative of 5 different mice for PBS and 6  
521 mice for the ZIKV infected group.